Atreca Inc BCEL:NASDAQ

Last Price$21.31Cboe Real-Time Last Sale as of 3:38PM ET 8/22/19
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+1.34(6.71%)
Bid (Size)$19.86 (100)
Ask (Size)$21.44 (200)
Day Low / High$19.33 - 23.38
Volume114.6 K
 

View Miscellaneous Commercial Services IndustryPeer Comparison as of 08/22/2019

 

Atreca Inc ( NASDAQ )

Price: $21.31
Change: +1.34 (6.71%)
Volume: 114.6 K
3:38PM ET 8/22/2019
 
 

Newtek Business Services Corp ( NASDAQ )

Price: $22.55
Change: +0.15 (0.67%)
Volume: 206.2 K
3:45PM ET 8/22/2019
 
 

Vectrus Inc ( NYSE )

Price: $41.43
Change: -0.05 (0.12%)
Volume: 35.7 K
1:30PM ET 8/22/2019
 
 

Willdan Group Inc ( NASDAQ )

Price: $35.70
Change: +0.08 (0.22%)
Volume: 10.7 K
2:59PM ET 8/22/2019
 
 

Hackett Group Inc ( NASDAQ )

Price: $16.17
Change: -0.06 (0.37%)
Volume: 19.2 K
3:45PM ET 8/22/2019
 

Read more news Recent News

Atreca Posts Narrower Q2 Loss
4:51AM ET 8/14/2019 MT Newswires

Drug maker Atreca (BCEL) reported late Tuesday a Q2 net loss of $3.67 per diluted share, narrower than the loss reported a year earlier of $4.13. Two...

Analyst Actions: Cowen Starts Atreca at Outperform
10:02AM ET 7/15/2019 MT Newswires

Atreca's (BCEL) average rating among analysts is a buy, with an average price target of $26. Price: 17.52, Change: +0.89, Percent Change: +5.37 ...

Analyst Actions: Evercore ISI Starts Atreca at Outperform, $35 PT
10:01AM ET 7/15/2019 MT Newswires

Atreca's (BCEL) average rating among analysts is a buy, with an average price target of $26. Price: 17.52, Change: +0.89, Percent Change: +5.37 ...

Analyst Actions: Canaccord Genuity Starts Atreca at Buy, With $23 Price Target
10:00AM ET 7/15/2019 MT Newswires

Atreca's (BCEL) average rating among analysts is a buy, with an average price target of $26. Price: 17.52, Change: +0.89, Percent Change: +5.37 ...

Company Profile

Business DescriptionAtreca, Inc. is a biopharmaceutical company. It develops novel therapeutics and immunotherapies based on a deep understanding of the human immune response. Its technology leverages next-generation sequencing to identify the set of functional antibodies produced in patients during an immune response. The company was founded by Robert Axtell, Guy Cavet, Jeremy Sokolove, Tito A. Serafini, Paulette A. Dillon, Daniel Emerling, Wayne Volkmuth, Jonathan Woo, Yann Chong Tan, William H. Robinson and Lawrence J. Steinman in June 11, 2010 and is headquartered in Redwood, CA. View company web site for more details
Address500 Saginaw Drive
Redwood, California 94063-4750
Phone+1.650.595.2595
Number of Employees85
President, Chief Executive Officer & DirectorJohn A. Orwin
Chief Financial OfficerHerbert C. Cross
Chief Technology OfficerGuy Cavet
Senior Vice President-ResearchDaniel Emerling

Company Highlights

Price Open$19.89
Previous Close$19.97
52 Week Range$10.29 - 23.38
Market Capitalization$469.1 M
Shares Outstanding22.0 M
SectorCommercial Services
IndustryMiscellaneous Commercial Services
Next Earnings Announcement11/12/2019

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$4.42
Beta vs. S&P 500N/A
Revenue$961.0 K
Net Profit Margin-2,798.86%
Return on Equity-138.50%

Analyst Ratings as of 07/12/2019

Buy
4
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset